Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Paragraph IV Challenges: An Overview
- The Current Landscape for Authorized Generics
- Strategies for Dealing with Exclusive Generics
- Consolidation and Integration of Brand and Generic Activities
- Discounting and Price Negotiations
- Generic Erosion
- Historic Patterns: Multiple Generics Enter the Market Upon Patent Expiry
- Generic Erosion with 180-Day Exclusivity: One Brand, One Generic
- The Payer Perspective: Can a Generic That Is Priced Lower Result in Less
Savings?
- Generalizable Rates of Erosion for Brands
- Implications for Authorized Generics
- Generic Erosion and the Authorized Generic Strategy
- Sidebar: How Can an Exclusive Generic Cost More than a Brand-Name Drug?
- The Three Competitive Scenarios: Example 1
- The Three Competitive Scenarios: Example 2
- A Recent Example of an Authorized Generic Strategy
- Authorized Generics: Not the Only Option
Tables
- 1. Select Brand Companies and Their Generic Subsidiaries
- 2. Key Payer Segments
- 3. Brand-Name Drug' s Share of the Market Under Two Scenarios
- Sidebar Table. Drug Pricing Chain
- 4. Generic Erosion: Three Competitive Scenarios
- 5. Generic Erosion in Three Basic Competitive Scenarios: Another Example
Figures
- 1. Historic Generic Erosion Rates of Drugs Facing Multiple Generic
Competition
- 2. Generic Erosion Rates of Drugs Facing a Single Generic Competitor
During the First 180 Days of Generic Entry
- 3. General Projected Brand Erosion to Generics During the First 180 Days
of Generic Entry
|
Related Report
|
View Cart
